A high pan-immune-inflammation value before chemoradiotherapy indicates poor outcomes in patients with small-cell lung cancer

• Published in: International journal of immunopathology and pharmacology 2023-01, Vol.37, p.3946320231187759-3946320231187759
• Main Authors: Kucuk, Ahmet, Topkan, Erkan, Ozkan, Emine Elif, Ozturk, Duriye, Pehlivan, Berrin, Selek, Ugur
• Format: Article
• Language: English
• Subjects: Chemoradiotherapy; Comparative analysis; Humans; Inflammation; Leukocytes (neutrophilic); Lung cancer; Lung Neoplasms - radiotherapy; Lymphocytes; Medical records; Monocytes; Multivariate analysis; Original; Patients; Peripheral blood; Population studies; Prognosis; Retrospective Studies; Small cell lung carcinoma; Small Cell Lung Carcinoma - therapy
• ISSN: 0394-6320; 2058-7384
• DOI: 10.1177/03946320231187759

Objectives: The objective of our study was to assess the prognostic significance of the Pan-Immune-Inflammation Value (PIV) before concurrent chemoradiation (C-CRT) and prophylactic cranial irradiation (PCI) in patients with limited-stage small-cell lung cancer (SCLC). Methods: The medical records of LS-SCLC patients who underwent C-CRT and PCI between January 2010 and December 2021 were retrospectively analyzed. PIV values were calculated using the peripheral blood samples obtained within the past 7 days before the initiation of treatment: PIV = [neutrophils × platelets × monocytes] ÷ lymphocytes. Using receiver operating characteristic (ROC) curve analysis, the optimal pretreatment PIV cutoff values that can partition the study population into two groups with substantially distinct progression-free survival (PFS) and overall survival (OS) outcomes were determined. The relationship between PIV values and OS outcomes was the primary outcome measure. Results: Eighty-nine eligible patients were divided into two PIV groups at an optimal cutoff of 417 [Area under curve (AUC): 73.2%; sensitivity: 70.4%; specificity: 66.7%]: Group 1: PIV < 417 (N = 36) and Group 2: PIV ≥ 417 (N = 53). Comparative analyses revealed that patients with PIV < 417 had significantly longer OS (25.0 vs 14.0 months, p < .001) and PFS (18.0 vs 8.9 months, p = .004) compared to patients with PIV ≥ 417. The outcomes of the multivariate analysis have verified the independent significance of pretreatment PIV concerning PFS (p < .001) and OS (p < .001) outcomes. Conclusion: The findings of this retrospective study indicate that the pretreatment PIV is a reliable and independent prognostic biomarker for patients with LS-SCLC who were treated with C-CRT and PCI.